SpaceX Regains $150 IPO Open Price as Defense Dept. Confirms Space-Based Weapons

SpaceX shares rose 5.1% to $151, reclaiming their $150 IPO opening level, after U.S. defense officials confirmed on-orbit space-control weapons and progress on the Golden Dome program. The Pentagon's FY2027 request includes $17.9B for Golden Dome capabilities, supporting the outlook for SpaceX's Starshield business, which holds more than $6B in multiyear Space Force contracts. The company also reported Q2 revenue of $7.81B, 15% above the $6.82B consensus, while Starlink subscribers doubled to 12.0M; however, the stock remains 33% below its June 16 intraday high of $226.

Analysis

The investable conclusion is conditional on source verification: SpaceX is not a currently listed NASDAQ security in widely recognized market data, and several cited financial and transaction figures require independent confirmation before capital is committed. A defense-policy headline alone is not equivalent to funded program awards; the relevant de-risking sequence is congressional appropriation, Missile Defense Agency/Space Force acquisition strategy, and named task orders. Until those occur, a sharp move in any purported SPCX instrument is more likely liquidity- and narrative-driven than a durable earnings re-rate.

For listed defense names, Golden Dome spending is unlikely to accrue evenly. LMT and RTX have the clearest near-term capture potential in interceptor, radar, and fire-control layers, while NOC is more exposed to classified payloads, sensors, and systems integration; the latter may be the cleaner 6-18 month beneficiary if the architecture favors proliferated sensing rather than a small number of exquisite platforms. The second-order risk is that a vertically integrated launch-and-constellation provider compresses prime-contractor economics by owning launch, bus production, and operations, leaving incumbents with lower-margin integration work.

RKLB has the highest positive operational read-through among listed space peers because sustained defense demand can improve launch utilization and create satellite-component opportunities, but its valuation remains highly sensitive to execution milestones rather than policy rhetoric. ASTS is a weaker read-through: defense interest in LEO communications does not validate its direct-to-device economics, spectrum position, or funding needs. Over the next 1-3 months, contract announcements and budget markups matter more than technical price levels; over 6-18 months, award concentration and fixed-price program margins determine whether sector multiples can hold.

Key Decisions for Investors

• Do not trade purported SPCX equity or derivatives until exchange listing, issuer filings, float, and custodial settlement are independently verified. Treat any inability to verify these items as a hard stop, not a valuation opportunity.
• Build a 3-6 month conditional long basket of LMT/RTX/NOC only after appropriations or named awards validate funding; favor NOC over equal-weight peers if sensing and command-and-control awards dominate. Size modestly ahead of budget passage because a continuing resolution or program redesign can defer revenue by 12+ months.
• Use RKLB as a tactical 1-3 month satellite/launch beta expression only on confirmed government award or launch-cadence evidence; cap risk with a stop below the pre-announcement level, as delayed Neutron execution or equity financing would overwhelm defense-sector sympathy.
• Avoid using ASTS as a Golden Dome proxy. Reassess only if it discloses a specific government contract with material minimum revenue commitments; otherwise its financing and commercialization milestones remain the primary drivers.
• Watch the FY budget authorization/appropriation calendar and subsequent Space Force/MDA solicitations. A failure to convert policy language into procurement by the next budget cycle falsifies the near-term defense-spend thesis and argues for reducing prime-contractor exposure.